<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042310</url>
  </required_header>
  <id_info>
    <org_study_id>18115</org_study_id>
    <secondary_id>J3K-MC-KIAA</secondary_id>
    <nct_id>NCT05042310</nct_id>
  </id_info>
  <brief_title>A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants</brief_title>
  <official_title>A Phase 1, Randomized, Participant- and Investigator-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3541860 in Healthy Japanese and Non-Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of LY3541860 in&#xD;
      healthy Japanese and non-Japanese participants. The study will also assess how fast LY3541860&#xD;
      gets into the blood stream and how long it takes the body to remove it. The study is open to&#xD;
      healthy participants. The study will last up to approximately 113 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 11, 2021</start_date>
  <completion_date type="Anticipated">October 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 113</time_frame>
    <description>A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3541860</measure>
    <time_frame>Predose on Day 1 through Day 113</time_frame>
    <description>PK: Cmax of LY3541860</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3541860</measure>
    <time_frame>Predose on Day 1 through Day 113</time_frame>
    <description>PK: AUC of LY3541860</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3541860 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of LY3541860 administered intravenously (IV) or subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3541860 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3541860 administered either IV or SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of Placebo administered either IV or SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of Placebo administered either IV or SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3541860</intervention_name>
    <description>Administered either IV or SC.</description>
    <arm_group_label>LY3541860 (Part A)</arm_group_label>
    <arm_group_label>LY3541860 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered either IV or SC.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are male or female not of childbearing potential&#xD;
&#xD;
          -  Have a body weight between 18 and 32 kilograms per square meter (kg/m²) and a body&#xD;
             weight ≥ 50 kilograms (kg)&#xD;
&#xD;
          -  Have veins suitable for blood sampling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have or used to have health problems or laboratory test results or ECG readings that,&#xD;
             in the opinion of the doctor, could make it unsafe to participate, or could interfere&#xD;
             with understanding the results of the study&#xD;
&#xD;
          -  Have active or latent TB&#xD;
&#xD;
          -  Have had breast cancer within the past 10 years or had lymphoma, leukemia, or any&#xD;
             malignancy within the past 5 years&#xD;
&#xD;
          -  Show clinical evidence of syphilis, HIV, hepatitis C, or hepatitis B, and/or test&#xD;
             positive&#xD;
&#xD;
          -  Have received treatment with biologic agents (such as monoclonal antibodies, including&#xD;
             marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.&#xD;
&#xD;
          -  Have previously completed a clinical trial investigating any other molecule targeting&#xD;
             CD19, CD20 or have previously discontinued from this study after receiving LY3541860&#xD;
&#xD;
          -  Are currently participating in or completed a clinical trial within the last 30 days&#xD;
&#xD;
          -  Have received a vaccine containing a live (attenuated) virus within 28 days of&#xD;
             screening or intend to receive during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>P-One Clinic</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <phone>81-80-1344-0786</phone>
    </contact>
    <investigator>
      <last_name>Kenichi Furihata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

